These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy. Tong JTW; Harris PWR; Brimble MA; Kavianinia I Molecules; 2021 Sep; 26(19):. PubMed ID: 34641391 [TBL] [Abstract][Full Text] [Related]
4. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads. Xi M; Zhu J; Zhang F; Shen H; Chen J; Xiao Z; Huangfu Y; Wu C; Sun H; Xia G Eur J Med Chem; 2024 Oct; 276():116709. PubMed ID: 39068862 [TBL] [Abstract][Full Text] [Related]
5. A Patent Review on FDA-Approved Antibody-Drug Conjugates, Their Linkers and Drug Payloads. Chia CSB ChemMedChem; 2022 Jun; 17(11):e202200032. PubMed ID: 35384350 [TBL] [Abstract][Full Text] [Related]
6. Antibody-Drug Conjugates for Cancer Therapy. Hafeez U; Parakh S; Gan HK; Scott AM Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383 [TBL] [Abstract][Full Text] [Related]
7. Antibody-drug conjugates: an emerging modality for the treatment of cancer. Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209 [TBL] [Abstract][Full Text] [Related]
9. Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy. Yaghoubi S; Karimi MH; Lotfinia M; Gharibi T; Mahi-Birjand M; Kavi E; Hosseini F; Sineh Sepehr K; Khatami M; Bagheri N; Abdollahpour-Alitappeh M J Cell Physiol; 2020 Jan; 235(1):31-64. PubMed ID: 31215038 [TBL] [Abstract][Full Text] [Related]
10. Antibody-Drug Conjugates: The New Frontier of Chemotherapy. Ponziani S; Di Vittorio G; Pitari G; Cimini AM; Ardini M; Gentile R; Iacobelli S; Sala G; Capone E; Flavell DJ; Ippoliti R; Giansanti F Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752132 [TBL] [Abstract][Full Text] [Related]
11. Site-specific antibody drug conjugates for cancer therapy. Panowski S; Bhakta S; Raab H; Polakis P; Junutula JR MAbs; 2014; 6(1):34-45. PubMed ID: 24423619 [TBL] [Abstract][Full Text] [Related]
12. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry. Hong Y; Nam SM; Moon A Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356 [TBL] [Abstract][Full Text] [Related]
13. The target invites a foe: antibody-drug conjugates in gynecologic oncology. Campos MP; Konecny GE Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302 [TBL] [Abstract][Full Text] [Related]
14. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Ferraro E; Drago JZ; Modi S Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530 [TBL] [Abstract][Full Text] [Related]
15. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Fu Z; Li S; Han S; Shi C; Zhang Y Signal Transduct Target Ther; 2022 Mar; 7(1):93. PubMed ID: 35318309 [TBL] [Abstract][Full Text] [Related]
16. Modeling to capture bystander-killing effect by released payload in target positive tumor cells. Byun JH; Jung IH BMC Cancer; 2019 Mar; 19(1):194. PubMed ID: 30832603 [TBL] [Abstract][Full Text] [Related]
17. Antibody drug conjugates beyond cytotoxic payloads. Hobson AD Prog Med Chem; 2023; 62():1-59. PubMed ID: 37981349 [TBL] [Abstract][Full Text] [Related]
18. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)]. Tsuchikama K Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230 [TBL] [Abstract][Full Text] [Related]
19. Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment. Pramanik D Anticancer Agents Med Chem; 2023; 23(6):642-657. PubMed ID: 36321237 [TBL] [Abstract][Full Text] [Related]